Advectus moves ahead with tumor treatment

Aug. 8, 2002 — Advectus Life Sciences said it’s planning a second animal study of its nanoparticle-based process of treating brain tumors after a successful first round.

The Canadian startup said the first phase, an in vitro study, found that the drugs delivered as nanoparticles remained effective throughout the entire process. University of North Carolina at Chapel Hill teamed up with Advectus on the study.

The second phase will test cancerous brain tumors of rodents. If successful, it could serve as a basis for human trials of the patented nanoparticle formulation, known as Nanocure.

Early tests showed that Nanocure delivers doxorubicin, a highly potent, anti-tumor drug that normally does not cross the blood-brain barrier.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.